Peptides That Help With Weight Loss: What Clinical Trials Actually Show

Some peptides do reduce body weight in controlled human trials, but only a narrow group: incretin-class agents such as tirzepatide, tested under clinical supervision with lifestyle support. Most other peptides marketed for weight loss lack comparable data. Everything Optides sells is for research use only, and this article describes published studies, not guidance.

Key takeaways

• In the 72-week SURMOUNT-1 trial in NEJM, mean weight change ranged from -15.0% to -20.9% across tirzepatide doses, versus about -3.1% with placebo.
• In SURMOUNT-3 (n=579), 10.5% of tirzepatide participants stopped treatment because of adverse events, versus 2.1% on placebo.
• A phase 2 retatrutide trial reported -24.2% at 48 weeks in the 12 mg group versus -2.1% on placebo, and its authors called for phase 3 confirmation.
• The FDA states that unapproved versions do not go through its review for safety, effectiveness and quality.

Which peptides have actually been tested for weight loss?

The peptides with real randomized trial data are the incretin-class agents. The incretin peptide class covers molecules that act on the GLP-1 receptor, the GIP receptor, or both, and in retatrutide's case the glucagon receptor as well. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is an investigational triple agonist of the GLP-1, GIP and glucagon receptors.

Other compounds often mentioned in weight-loss conversations, such as AOD-9604 (a fragment of the growth-hormone molecule) or MOTS-c (a mitochondrial-derived peptide), sit in a different place on the evidence ladder. The table below separates what has been tested in humans from what has not.

Compound	Evidence tier	Trial length reported here	Headline weight result
Tirzepatide (dual GIP/GLP-1 agonist)	Human phase 3 randomized trials	72 weeks	-15.0% to -20.9% (SURMOUNT-1) versus about -3.1% placebo
Retatrutide (triple agonist)	Human phase 2 randomized trial, investigational	48 weeks	-8.7% to -24.2% versus -2.1% placebo
Peptides without randomized weight-loss trials	Cell culture, animal studies or none	Not applicable	No comparable human data in the sources reviewed here

What did the tirzepatide trials measure?

They measured percentage change in body weight over 72 weeks in adults with obesity or overweight, using a placebo group and lifestyle support in every arm.

SURMOUNT-1: adults without diabetes

SURMOUNT-1 randomized adults with obesity or overweight, without diabetes, 1:1:1:1 to once-weekly tirzepatide at 5, 10 or 15 mg, or placebo, with a dose-escalation period of up to 20 weeks. The NEJM report gave mean weight change at week 72 of -15.0%, -19.5% and -20.9% across the three doses, compared with about -3.1% for placebo. Weight loss of at least 5% was reached by 85%, 89% and 91% of participants across the three tirzepatide doses, versus 35% on placebo. The trial was sponsored by Eli Lilly.

SURMOUNT-3: after a lifestyle lead-in

SURMOUNT-3 enrolled 579 adults who had already lost at least 5.0% of body weight during a 12-week intensive lifestyle lead-in. As the published report describes, participants were then assigned to tirzepatide at the maximum tolerated dose (10 or 15 mg) or placebo for 72 weeks. Additional weight change was -18.4% with tirzepatide versus +2.5% with placebo, a treatment difference of -20.8 percentage points (95% CI -23.2 to -18.5). An additional reduction of at least 5% occurred in 87.5% versus 16.5%.

What the endpoints do and do not say

The headline figures are group averages of percent body weight, produced in a supervised, sponsor-funded setting with lifestyle support. They describe what happened to participants taking a specific product under a specific regimen. They don't predict outcomes for any other compound. The dual GIP/GLP-1 design covered in our piece on dual GIP/GLP-1 receptor pharmacology belongs to that molecule, not to peptides in general.

What did the retatrutide phase 2 trial show?

The weight reductions were large and dose-related over 48 weeks. The evidence is still early-stage. According to the phase 2 report in NEJM, the least-squares mean weight change at 48 weeks was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group and -24.2% in the 12 mg group, against -2.1% for placebo. At 24 weeks the 12 mg group averaged about -17.5% versus -1.6% on placebo. In the 12 mg group, 100%, 93% and 83% of participants lost at least 5%, 10% and 15% of body weight, compared with 27%, 9% and 2% on placebo. The authors called for phase 3 confirmation.

For how the molecule is built, see triple- versus dual-agonist design.

The liver-fat substudy

A 48-week substudy in 98 adults with metabolic dysfunction-associated steatotic liver disease, published in Nature Medicine, reported body weight changes of -8.6%, -16.3%, -23.8% and -25.9% across the four retatrutide doses versus -0.1% for placebo, with relative liver fat falling by -51.3% to -86.0% versus -4.6%. The caveats are in the paper itself: only 43.9% of participants had week-48 MRI data, completion was uneven across arms, and the authors describe the results as hypothesis-generating and not definitive.

What side effects showed up in the trials?

Gastrointestinal events were the most common adverse events in these studies, mostly mild to moderate. In SURMOUNT-1 they occurred mainly during dose escalation. In SURMOUNT-3, 87.1% of tirzepatide participants (250 of 287) reported at least one adverse event versus 76.7% on placebo (224 of 292), and 10.5% (30 of 287) discontinued because of adverse events versus 2.1% (6 of 292).

In the retatrutide liver substudy, transient and generally mild-to-moderate gastrointestinal events were also the most frequent, and they were more frequent at the 8 mg and 12 mg doses. Two retatrutide participants (2.5%) had three serious adverse events, and no hepatotoxicity signal was seen through 48 weeks. Those are figures researchers recorded in supervised trials, nothing more.

Why do meta-analyses of these trials need careful reading?

Pooling blends different agents, doses, populations and endpoints into one number. A meta-analysis of 47 randomized trials of GLP-1 receptor agonists found a mean reduction of about 4.6 kg, a figure far from the percentages above because it averages the whole class, including smaller-effect agents. A more recent systematic review of 16 placebo-controlled trials (n=7,024) used a loose endpoint, the proportion of participants achieving any weight loss, which was 78.54% versus 26.53% on placebo. That review also reported high heterogeneity (I² = 82%), a PubMed-only English-language search, and no registered protocol, and it did not analyze adverse events.

Meta-analyses aren't useless. But a pooled figure says little about any single compound, and "any weight loss" isn't the same as clinically meaningful loss.

Do trial results apply to research-grade peptides?

No. Tirzepatide and retatrutide are INN names shared with pharmaceutical products and investigational drugs, but research-grade material is not the FDA-approved pharmaceutical of the same name. Trial outcomes belong to the tested product, regimen and supervision. For more on the labeling side, see what a "not for human use" label means.

The FDA's page on unapproved GLP-1 drugs used for weight loss (current as of October 2026) says that "unapproved versions do not undergo FDA's review for safety, effectiveness and quality before they are marketed." It also states that retatrutide "cannot be used in compounding under federal law" and has not been shown safe and effective for any condition. The agency reports dosing errors, some requiring hospitalization, fraudulent labels, and products labeled "for research purposes" or "not for human consumption" that are sold for human use. As of May 31, 2026, it had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and notes these are likely underreported.

We make no claim that any Optides product does anything in people. These studies show what specific agents did in specific trials, and that's all.

Bottom line: what the evidence supports

Incretin-class peptides have genuine randomized trial data, with tirzepatide furthest along and retatrutide earlier in development. Everything else sold under the label of weight-loss peptides is cell-culture, animal, or anecdotal territory. Reading a trial well means checking the endpoint, the comparator, the sponsor, the attrition, and whether the product you are reading about is the product that was tested.

Frequently Asked Questions

What peptides help with weight loss?

In published human trials, the peptide-based agents with the largest measured weight reductions are incretin-class molecules such as tirzepatide (approved) and retatrutide (investigational). Other peptides marketed for weight loss lack comparable randomized trial data.

Do peptides really work for weight loss?

Specific incretin-based peptides reduced body weight versus placebo in large controlled trials, alongside lifestyle support. That result does not extend to peptides in general, nor to unapproved or research-labeled products.

What are the side effects of weight loss peptides in clinical trials?

Gastrointestinal events were the most common, mostly mild to moderate and concentrated during dose escalation. In SURMOUNT-3, 10.5% of tirzepatide participants stopped because of adverse events versus 2.1% on placebo.

Are research peptides the same as the drugs used in these trials?

No. Research-grade material is not the FDA-approved pharmaceutical of the same name, and the FDA states that unapproved versions skip its review for safety, effectiveness and quality.

Is retatrutide approved?

Retatrutide is investigational, with phase 2 data published and phase 3 confirmation called for by the trial authors. The FDA states it cannot be used in compounding under federal law.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.